Atogepant (Qulipta) vs Rimegepant (Nurtec ODT)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Atogepant (Qulipta)

Marketed by AbbVie

Approved in Migrainesmall molecule
Reliable signal

NCT03777059 · Phase 3 · completed

The study was randomized, double-blind, and placebo-controlled, with 910 participants and a clinically meaningful primary endpoint based on change in monthly migraine days. The primary comparison was statistically significant in favor of atogepant for 10 mg, 30 mg, and 60 mg doses, each with p<0.0001.

Next expected readout: March 2028 · NCT05711394 (registry estimate)

Reported efficacy

Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) (met)

Result source: NCT03777059

Rimegepant (Nurtec ODT)

Marketed by Pfizer and partners

Approved in Migrainesmall molecule
Reliable signal

NCT03235479 · Phase 3 · completed

This was a randomized, triple-masked, placebo-controlled trial with 1,162 randomized participants. Its two primary clinical endpoints were met: 2-hour pain freedom was 19.2% with rimegepant versus 14.2% with placebo (p=0.0298), and freedom from the most bothersome symptom was 36.6% versus 27.7% (p=0.0016).

Next expected readout: November 2026 · NCT06641466 (registry estimate)

Reported efficacy

Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) (met)

Result source: NCT05810038

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Atogepant (Qulipta)
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) NCT03777059 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33) NCT02848326 · Phase 2/3 · design grade: strong · reviewed ClinicalTrials.gov result
Rimegepant (Nurtec ODT)
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase (OP and Weeks 9 to 12 of the DBT phase): Rimegepant - Randomization Phase -4.3 Total Migraine Days per Month (95% CI -4.83 to -3.87) | Placebo - Randomization Phase -3.5 Total Migraine Days per Month (95% CI -4 to -3.04) NCT03732638 · Phase 2/3 · design grade: moderate · reviewed ClinicalTrials.gov result
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05810038 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) NCT05399485 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atogepant (Qulipta)'s landscape · Rimegepant (Nurtec ODT)'s landscape